Trials / Recruiting
RecruitingNCT06875960
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days |
Timeline
- Start date
- 2026-02-24
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-03-14
- Last updated
- 2026-03-30
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06875960. Inclusion in this directory is not an endorsement.